Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Dr David Koren on At-Risk Populations, Educational Efforts in Monkeypox
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, discussed the risk posed by monkeypox among immunocompromised individuals and men who have sex with men, as well as the need for educational efforts to address misconceptions tied to the disease.
Rifaximin Plus Lactulose Linked to Greater Effectiveness, Decreased Mortality in HE
Compared with the use of lactulose alone, rifaximin plus lactulose can provide additional benefits in terms of increased effectiveness rate and decreased mortality in patients with hepatic encephalopathy (HE).
Survey Reveals Injectable HIV PrEP Preferences of Young Men Who Have Sex With Men
Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and delivery method.
Gamified Therapy PDT Yields High Support From Children With Neurodevelopmental Disabilities
A digital pet app used as a prescription digital therapeutic (PDT) to encourage children to complete prescribed therapies received high engagement and function scores from children living with neurodevelopmental disabilities.
Dr David Koren Discusses Response to the Monkeypox Public Health Emergency
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, speaks on gaps in monkeypox vaccine availability and access and steps to improve response to the public health emergency.
Gap After OCM May Cause Some Practices to Switch From Biosimilars to Brand Drugs
The 1-year gap after the end of the Oncology Care Model (OCM) means some practices have to make hard decisions regarding cost of care or the financial health of the practice, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Immune Responses to ART Vary by Regimen Among Individuals With Advanced HIV
People with advanced HIV initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were more likely to reach CD4 cell count levels of 200 cells/mcL or higher compared with those initiating other antiretroviral therapy (ART) regimens.
Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC
Hatim Husain, MD, associate professor in the Department of Medicine at UC San Diego, discuses must-haves for successful biomarker testing in lung cancer—in particular, non–small cell lung cancer (NSCLC)—and how the field is adapting to the targeted treatment needs of its patients.
Black, Latinx Transgender Women Cite Multiple Motivations for PrEP Use
Black and Latinx transgender women expressed high levels of HIV risk perception at the individual and community level, both of which played major roles in their decision to start and continue pre-exposure prophylaxis (PrEP).
QCCA Panel Highlights Expansion of Innovation at Independent Community Oncology
Value management, theranostics, clinical trial access, and a mobile pharmacy are major innovations being integrated into independent community oncology practices, as highlighted at the Quality Cancer Care Alliance Summer 2022 National Leadership Summit.
ACR Releases 2022 Vaccination Guideline Summary for Patients With RMDs
The summary includes expanded indications for certain vaccines, approaches for live-attenuated vaccines, and medication management around the time of vaccination for patients with rheumatic and musculoskeletal diseases (RMDs).
Review Highlights Major RA Management Developments in Past Year
According to the review, the most important novel developments were related to the repositioning of old drugs in the context of treat-to-target (T2T) therapy and new long-term safety information on Janus kinase (JAK) inhibitors.